In the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), researchers found that liraglutide reduced the risk of cardiovascular events in diabetic patients, including heart attack, stroke, and cardiovascular death, by 13% compared to placebo
Furthermore, Ohsawa et al., conducted a multicenter, phase III research that includes 10 patients with recurring stroke-like events
(2013) A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Ideal for those who want to minimize side effects, maintain current progress, or ease into the medication
Step 2: Use a Structured Self-Check While waiting for appointments or results, start a health diary